Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Entia Biosciences, Inc. (ERGO)
Sherwood, OR, US
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | 0.00% | +100.00% | +500.00% | +100.00% | +500.00% | +500.00% | -97.75% | -99.24% | -99.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Pharmaceuticals: +7.8%-23.5% Q4'16: -32.8% (vs Q4'15)
-
EPS growth Medical - Pharmaceuticals: +20.2%+47.3% ★ Q4'16: -57.5% (vs Q4'15)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-369.1% Q4'16: -956.7% (vs Q4'15)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-494.3% Q4'16: -846.3% (vs Q4'15)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q4'16: +156.2% (vs Q4'15)
-
Share dilution Medical - Pharmaceuticals: +0.0%+15.8% Q4'16: -3.3% (vs Q4'15)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.81× Q4'16: -0.68× (vs Q4'15)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-02-16 | JOHNSON CARL J | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 850,000 | — | ↗ |
| 2017-02-16 | HAUSMAN MARVIN S MD | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 10,188,900 | — | ↗ |
| 2017-02-14 | JOHNSON CARL J | Director / Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 600,000 | — | ↗ |
| 2017-02-14 | HAUSMAN MARVIN S MD | Director / Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 9,938,900 | — | ↗ |
| 2016-12-05 | HAUSMAN MARVIN S MD | Officer | P-Purchase | A | 10% Convertible | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-05-20 | JOHNSON CARL J | Director / Officer | P-Purchase | A | 8% Conv Debenture | 0 | 0.10 | — | 250,000 | — | ↗ |
| 2015-08-12 | JOHNSON CARL J | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-05-08 | WONG WAH ON EDWARD | 10% Owner | A-Award | A | Common Stock | 1,025,462 | 0.01 | 10.3K | 1,521,228 | — | ↗ |
| 2015-05-08 | ANKA CAPITAL LTD | 10% Owner | A-Award | A | Common Stock | 2,050,923 | 0.01 | 20.5K | 3,042,455 | — | ↗ |
| 2015-04-24 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | A-Award | A | Common Stock | 600,000 | 0.20 | 120.0K | 4,757,200 | — | ↗ |
| 2014-12-31 | WONG WAH ON EDWARD | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 495,766 | — | ↗ |
| 2014-12-31 | ANKA CAPITAL LTD | 10% Owner | — | I | Common Stock Purchase Warrant | 368,750 | 0.01 | 3.7K | 0 | — | ↗ |
| 2014-09-29 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | A-Award | A | Incentive stock option | 175,000 | 0.40 | 70.0K | 175,000 | — | ↗ |
| 2014-09-25 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK | 2,162,980 | 0.30 | 648.9K | 4,171,825 | — | ↗ |
| 2013-12-17 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK | 62,505 | 0.38 | 23.8K | 2,482,488 | — | ↗ |
| 2013-11-04 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | A-Award | A | Common Stock Purchase Warrant | 7,313 | 1.00 | 7.3K | 7,313 | — | ↗ |
| 2013-07-12 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | P-Purchase | A | COMMON STOCK | 131,579 | 0.38 | 50.0K | 2,419,981 | — | ↗ |
| 2013-07-11 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | A-Award | A | Common Stock Purchase Warrant | 400,000 | 0.45 | 180.0K | 400,000 | — | ↗ |
| 2013-06-11 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | P-Purchase | A | Series A Preferred Stock | 16,025 | 0.50 | 8.0K | 21,025 | — | ↗ |
| 2013-01-17 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | A-Award | A | Series A Preferred Stock | 1,000 | 0.50 | 500.00 | 4,000 | — | ↗ |
| 2012-11-20 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | A-Award | A | Series A Preferrred Stock | 3,000 | 0.50 | 1.5K | 3,000 | — | ↗ |
| 2012-05-30 | HAUSMAN MARVIN S MD | Director / Officer / 10% Owner | P-Purchase | A | Series A Preferred Stock | 1,000 | 0.50 | 500.00 | 5,000 | — | ↗ |
| 2003-08-04 | CITIGROUP INC | Other | D-Return | D | Common Stock | 1,335,722 | 1.81 | 2.42M | 304,233 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marvin S. Hausman | Chairman and Chief Science & Technology Officer | 174.0K | — |
| Timothy A. Timmins | Chief Executive Officer & President | 141.5K | male |
| Elliot A. L. Shelton | Secretary and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ERGO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
